The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis

Immunopharmacology and Immunotoxicology

Volumn 33, Issue 4, 2011, Pages 667-675

  Aktunc, Erol ^a   Kayhan, Basak ^b   Arasli, Mehmet ^a   Gun, Banu Dogan ^a   Barut, Figen ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Cytokines; Inflammatory bowel diseases; Statin; Systemic immune response; Th1; Th17; Th2

Indexed keywords

ATORVASTATIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADHESION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; COLITIS; COLON; COLON ULCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM HEMORRHAGE; SURVIVAL; TH1 CELL; TH17 CELL; TH2 CELL;

ACUTE DISEASE; ANIMALS; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; PYRROLES; TH1 CELLS; TH2 CELLS;

MUS;

EID: 80755143841     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.559475     Document Type: Article

References (37)

1. Weber, C.R., Turner, J.R. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007, 56, 6-8. (Pubitemid 46044880)
2. Hollander, D. Crohn's disease-a permeability disorder of the tight junction? Gut 1988, 29, 1621-1624.
3. Karlinger, K., Györke, T., Makö, E., Mester, A., Tarján, Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000, 35, 154-167.
4. Koutroubakis, I., Manousos, O.N., Meuwissen, S.G., Pena, A.S. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996, 43, 381-393. (Pubitemid 26111959)
5. Bamias, G., Cominelli, F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007, 23, 365-369. (Pubitemid 46878946)
6. Shih, D.Q., Targan, S.R. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008, 14, 390-400. (Pubitemid 351320847)
7. Rogler, G., Andus, T. Cytokines in inflammatory bowel disease. World J Surg 1998, 22, 382-389. (Pubitemid 28113526)
8. Kolls, J.K., Lindén, A. Interleukin-17 family members and inflammation. Immunity 2004, 21, 467-476. (Pubitemid 39370503)
9. Gross, V., Andus, T., Caesar, I., Roth, M., Schölmerich, J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992, 102, 514-519.
10. Plevy, S.E., Landers, C.J., Prehn, J., Carramanzana, N.M., Deem, R.L., Shealy, D., Targan, S.R. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997, 159, 6276-6282. (Pubitemid 127471570)
11. Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M.A., Owyang, A., Mattson, J., Blumenschein, W., Murphy, E., Sathe, M., Cua, D.J., Kastelein, R.A., Rennick, D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116, 1310-1316.
12. Sandborn, W.J., Targan, S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122, 1592-1608. (Pubitemid 34533555)
13. Van Deventer, S.J. Immunotherapy of Crohn's disease. Scand J Immunol 2000, 51, 18-22.
14. Targan, S.R., Feagan, B.G., Fedorak, R.N., Lashner, B.A., Panaccione, R., Present, D.H., Spehlmann, M.E., Rutgeerts, P.J., Tulassay, Z., Volfova, M., Wolf, D.C., Hernandez, C., Bornstein, J., Sandborn, W.J.; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007, 132, 1672-1683.
15. + T cells. J Exp Med 1996, 183, 2669-2674.
16. Corsini, A., Maggi, F.M., Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995, 31, 9-27.
17. Kitamoto, S., Egashira, K. [Anti-inflammatory effect of HMG-CoA reductase inhibitors]. Nippon Rinsho 2004, 62, 172-179.
18. Stumpf, C., Petzi, S., Seybold, K., Wasmeier, G., Arnold, M., Raaz, D., Yilmaz, A., Daniel, W.G., Garlichs, C.D. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci 2009, 116, 45-52.
19. Montecucco, F., Mach, F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009, 31, 127-142.
20. Kwak, B., Mulhaupt, F., Myit, S., Mach, F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6, 1399-1402. (Pubitemid 32001026)
21. Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7, 687-692. (Pubitemid 32588024)
22. Aharoni, R., Kayhan, B., Arnon, R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis 2005, 11, 106-115. (Pubitemid 40711214)
23. Reuter, B.K., Asfaha, S., Buret, A., Sharkey, K.A., Wallace, J.L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996, 98, 2076-2085. (Pubitemid 26376296)
24. Aharoni, R., Kayhan, B., Brenner, O., Domev, H., Labunskay, G., Arnon, R. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 2006, 318, 68-78.
25. Mayer, L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010, 45, 9-16.
26. Levine, A. Pediatric inflammatory bowel disease: is it different? Dig Dis 2009, 27, 212-214.
27. Kamm, C.P., Mattle, H.P.; SWABIMS Study Group. SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)- rationale, design and methodology. Trials 2009, 10, 115.
28. Nikitina, N.M., Rebrov, A.P. [The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia]. Kardiologiia 2009, 49, 21-26.
29. Ljuca, F., Gegic, A., Salkic, N.N., Pavlovic-Calic, N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Dig Dis Sci 2010, 55, 2316-2326.
30. D'haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., Rutgeerts, P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116, 1029-1034. (Pubitemid 29203012)
31. Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S.B., Present, D.H., Mayer, L., Van Hogezand, R.A., Braakman, T., DeWoody, K.L., Schaible, T.F., Van Deventer, S.J. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117, 761-769. (Pubitemid 29468216)
32. Lee, J.Y., Kim, J.S., Kim, J.M., Kim, N., Jung, H.C., Song, I.S. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007, 7, 241-248. (Pubitemid 46037564)
33. Ikeda, M., Takeshima, F., Isomoto, H., Shikuwa, S., Mizuta, Y., Ozono, Y., Kohno, S. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. Dig Dis Sci 2008, 53, 1869-1875.
34. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278, 1910-1914. (Pubitemid 36801431)
35. + T cell population of rheumatoid arthritis patients. Immunol Lett 2010, 127, 150-156.
36. Cheng, X., Ding, Y., Xia, C., Tang, T., Yu, X., Xie, J., Liao, M., Yao, R., Chen, Y., Wang, M., Liao, Y.H. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 2009, 15, 158-162.
37. Wei, L., Wei-Min, L., Cheng, G., Ning-Ling, S. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 2005, 25, 258-263.